Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: Validation and its application to a human pharmacokinetic study

Biomedical Chromatography

Volumn 23, Issue 8, 2009, Pages 804-810

  Bharathi, D Vijaya ^a,b   Hotha, Kishore Kumar ^a   Jagadeesh, B ^a   Mullangi, Ramesh ^a   Naidu, A ^b  

^a DR REDDY'S LABORATORIES LTD   (India)

^b JNTUH COLLEGE OF ENGINEERING   (India)

Author keywords

Human plasma; LC MS MS; Method validation; Montelukast; Pharmacokinetics

Indexed keywords

MASS SPECTROMETRY; PLASMA (HUMAN); POSITIVE IONS;

HUMAN PLASMAS; INTERNAL STANDARDS; ITS APPLICATIONS; LC-MS-MS; LC.MS/MS; LEUKOTRIEN; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; METHOD VALIDATIONS; MONTELUKAST; PHARMACOKINETIC STUDIES;

PHARMACOKINETICS;

ACETONITRILE; AMLODIPINE; AMMONIUM ACETATE; MONTELUKAST;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROSPRAY; FLOW RATE; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MAXIMUM PLASMA CONCENTRATION; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY;

EID: 70349507019     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1189     Document Type: Article

References (15)

1. Al-Rawithi S, Al-Gazlan S, Al-Ahmadi W, Alshowaier IA, Yusuf A and Raines DA. Expedient liquid chromatographic method with fluorescence detection for montelukast sodium in micro-samples of plasma. Journal of Chromatography B 2001; 754: 527-531.
2. Amin RD, Cheng H and Rogers JD. Determination of MK-0476 in human plasma by liquid chromatography. Journal of Pharmaceutical Biomedical Analysis 1995; 13: 155-158.
3. Balani SK, Xu S, Pratha V, Koss MA, Amin RD, Dufresne C, Miller RR, Arison BH, Doss GA, Chiba M, Freeman A, Holland SD, Schwartz JI, Lasseter KC, Gertz BJ, Isenberg JI, Rogers JD, Lin JH and Baillie TA. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metabolsim and Disposition 1997; 25: 1282-1287.
4. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D and Somers G. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharmaceutical Research 1996; 13: 445-448.
5. Dams R, Huestis MA, Lambert WE and Murphy CM. Matrix effect in bioanalysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. Journal of American Society for Mass Spectrometry 2003; 14: 1290-1294.
6. Hubert Ph, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, Bervoas-Martin S, Chevalier P, Grandjean D, Lagorce P, Lallier M, Laparra MC, Laurentie M and Nivet JC. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis Washington conference to the laboratory. Analytica Chimica Acta 1999; 391: 135-148.
7. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hutchinson AW, Gauthier JY, Lord A, Masson P, McAuliffe M, McFarlane CS, Metters KM, Pickett C, Pichuta H, Rochette C, Rodger IW, Swayer N, Yoyng RN, Zamboni R and Abraham WM. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Canadian Journal of Physiology and Pharmacology 1995; 73: 191-201.
8. Kitchen CJ, Wang AQ, Musson DG, Yang AY and Fisher AL. A semi-automated 96-well protein precipitation method for the determination of montelukast in human plasma using high performance liquid chromatography/ fluorescence detection. Journal of Pharmaceutical Biomedical Analysis 2003; 3: 647-654.
9. Knorr B, Holland S, Schwartz J, Rogers JD and Reiss TF. Clinical pharmacology of montelukast. Clinical and Experimental Allergy Reviews 2001, 1: 254-260.
10. Liu L, Cheng H, Zhao JJ and Rogers JD. Determination of montelukast (MK-0476) and its S-enantiomer in human plasma by stereoselective high-performance liquid chromatography with column-switching. Journal of Pharmaceutical Biomedical Analysis 1997; 15: 631-638.
11. Ochiai H, Uchiyama N, Takano T, Hara K and Kamei T. Determination of montelukast sodium in human plasma by column-switching high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B 1998; 713: 409-414.
12. Papp R, Luk P, Mullett WM and Kwong E. A rapid and sensitive method for the quantitation of montelukast in sheep plasma using liquid chromatography/tandem mass spectrometry. Journal of Chromatography B 2007; 858: 282-286.
13. Singulairr. Montelukast sodium tablets and chewable tablets. Prescribing information. Merck Inc., Whitehouse Station, NJ, USA. March, 2000.
14. Sripalakit P, Kongthong B and Saraphanchotiwitthaya A. A simple bioanalytical assay for determination of montelukast in human plasma: application to a pharmacokinetic study. Journal of Chromatography B 2008; 869: 38-44.
15. US DHHS, FDA and CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001. Available at: http://www.fda.gov/cder/ guidance/index.htm